Michael Weisser, Lukas Richards, Ned Schultheis, Oliver Yee, D. Kim Grinhaus, Ahmed Imam, Jared Rusman, Liz Allison, Mike Krasnovsky, Annemarie Mierzejewski, Jason Serlenga, Katie Taylor
January 24, 2026
Kirkland Advises TJC on Sale of Worldwide Clinical Trials

1 min
AI-made summary
- Kirkland & Ellis represented private equity firm TJC and its affiliate, Worldwide Clinical Trials, in the sale of the contract research organization to Kohlberg & Company, LLC
- The transaction was announced on August 7 and is anticipated to close in the fourth quarter of 2023
- TJC will retain a significant minority equity interest in Worldwide Clinical Trials, which collaborates with biotechnology and pharmaceutical companies to develop new medications.
Kirkland & Ellis advised private equity firm TJC and its affiliate company Worldwide Clinical Trials on the sale of the contract research organization to private equity firm Kohlberg & Company, LLC. The deal was announced August 7 and is expected to close in the fourth quarter of 2023. TJC will hold onto a meaningful minority equity stake in Worldwide Clinical Trials, which works in partnership with biotechnology and pharmaceutical companies to create customized solutions to advance new medications from discovery to reality. Read the transaction press release The Kirkland team was led by corporate partners Michael Weisser, Lukas Richards and Ned Schultheis and associates Oliver Yee, D. Kim Grinhaus and Ahmed Imam; tax partner Jared Rusman and associate Liz Allison; executive compensation partner Mike Krasnovsky and associate Annemarie Mierzejewski; and debt finance partners Jason Serlenga and Katie Taylor.
Article Author
Michael Weisser, Lukas Richards, Ned Schultheis, Oliver Yee, D. Kim Grinhaus, Ahmed Imam, Jared Rusman, Liz Allison, Mike Krasnovsky, Annemarie Mierzejewski, Jason Serlenga, Katie Taylor
The Sponsor
